Shares of BeyondSpring Inc. (NASDAQ:BYSI) have been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.

Brokers have set a one year consensus target price of $56.00 for the company and are predicting that the company will post ($0.79) EPS for the current quarter, according to Zacks. Zacks has also assigned BeyondSpring an industry rank of 98 out of 265 based on the ratings given to related companies.

Several research firms have recently weighed in on BYSI. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of BeyondSpring in a research report on Monday, August 21st. Zacks Investment Research cut shares of BeyondSpring from a “hold” rating to a “sell” rating in a research report on Monday, November 13th. Finally, Maxim Group reiterated a “buy” rating and set a $52.00 price objective on shares of BeyondSpring in a research report on Friday, October 27th.

An institutional investor recently bought a new position in BeyondSpring stock. Tanaka Capital Management Inc. acquired a new position in shares of BeyondSpring Inc. (NASDAQ:BYSI) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 21,322 shares of the company’s stock, valued at approximately $914,000. BeyondSpring accounts for approximately 2.1% of Tanaka Capital Management Inc.’s holdings, making the stock its 16th biggest holding. Tanaka Capital Management Inc. owned about 0.10% of BeyondSpring at the end of the most recent reporting period. Institutional investors and hedge funds own 1.22% of the company’s stock.

BeyondSpring (BYSI) opened at $32.51 on Tuesday. BeyondSpring has a 12-month low of $16.55 and a 12-month high of $48.49.

BeyondSpring (NASDAQ:BYSI) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.69) by $0.01. equities research analysts expect that BeyondSpring will post -4.41 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Zacks: BeyondSpring Inc. (BYSI) Given $56.00 Average Price Target by Brokerages” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at

BeyondSpring Company Profile

BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).

Get a free copy of the Zacks research report on BeyondSpring (BYSI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with's FREE daily email newsletter.